Design and Endpoints for Clinical Trials in Primary Sclerosing Cholangitis

Cyriel Y. Ponsioen, Keith Lindor, Ruby Mehta, Lara Dimick-Santos

Research output: Contribution to journalReview article

6 Citations (Scopus)

Abstract

Primary sclerosing cholangitis (PSC) is a rare and chronic liver disease for which there is no effective therapy. Interest has grown in developing treatments for this condition, with several agents proposed as potential therapies. However, there is a lack of clarity about how to measure clinical benefit in trials involving patients with this complex and rare disease. This article reviews regulatory information, the available literature on natural history, as well as potential candidate clinical and surrogate endpoints for PSC. (Hepatology 2018; 00:000-000).

Original languageEnglish (US)
Pages (from-to)1174-1188
Number of pages15
JournalHepatology
Volume68
Issue number3
DOIs
StatePublished - Sep 1 2018

Fingerprint

Sclerosing Cholangitis
Clinical Trials
Gastroenterology
Rare Diseases
Natural History
Liver Diseases
Chronic Disease
Therapeutics
Biomarkers

ASJC Scopus subject areas

  • Hepatology

Cite this

Design and Endpoints for Clinical Trials in Primary Sclerosing Cholangitis. / Ponsioen, Cyriel Y.; Lindor, Keith; Mehta, Ruby; Dimick-Santos, Lara.

In: Hepatology, Vol. 68, No. 3, 01.09.2018, p. 1174-1188.

Research output: Contribution to journalReview article

Ponsioen, Cyriel Y. ; Lindor, Keith ; Mehta, Ruby ; Dimick-Santos, Lara. / Design and Endpoints for Clinical Trials in Primary Sclerosing Cholangitis. In: Hepatology. 2018 ; Vol. 68, No. 3. pp. 1174-1188.
@article{0da656e897934a86bb7640a81e6146fd,
title = "Design and Endpoints for Clinical Trials in Primary Sclerosing Cholangitis",
abstract = "Primary sclerosing cholangitis (PSC) is a rare and chronic liver disease for which there is no effective therapy. Interest has grown in developing treatments for this condition, with several agents proposed as potential therapies. However, there is a lack of clarity about how to measure clinical benefit in trials involving patients with this complex and rare disease. This article reviews regulatory information, the available literature on natural history, as well as potential candidate clinical and surrogate endpoints for PSC. (Hepatology 2018; 00:000-000).",
author = "Ponsioen, {Cyriel Y.} and Keith Lindor and Ruby Mehta and Lara Dimick-Santos",
year = "2018",
month = "9",
day = "1",
doi = "10.1002/hep.29882",
language = "English (US)",
volume = "68",
pages = "1174--1188",
journal = "Hepatology",
issn = "0270-9139",
publisher = "John Wiley and Sons Ltd",
number = "3",

}

TY - JOUR

T1 - Design and Endpoints for Clinical Trials in Primary Sclerosing Cholangitis

AU - Ponsioen, Cyriel Y.

AU - Lindor, Keith

AU - Mehta, Ruby

AU - Dimick-Santos, Lara

PY - 2018/9/1

Y1 - 2018/9/1

N2 - Primary sclerosing cholangitis (PSC) is a rare and chronic liver disease for which there is no effective therapy. Interest has grown in developing treatments for this condition, with several agents proposed as potential therapies. However, there is a lack of clarity about how to measure clinical benefit in trials involving patients with this complex and rare disease. This article reviews regulatory information, the available literature on natural history, as well as potential candidate clinical and surrogate endpoints for PSC. (Hepatology 2018; 00:000-000).

AB - Primary sclerosing cholangitis (PSC) is a rare and chronic liver disease for which there is no effective therapy. Interest has grown in developing treatments for this condition, with several agents proposed as potential therapies. However, there is a lack of clarity about how to measure clinical benefit in trials involving patients with this complex and rare disease. This article reviews regulatory information, the available literature on natural history, as well as potential candidate clinical and surrogate endpoints for PSC. (Hepatology 2018; 00:000-000).

UR - http://www.scopus.com/inward/record.url?scp=85046949847&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85046949847&partnerID=8YFLogxK

U2 - 10.1002/hep.29882

DO - 10.1002/hep.29882

M3 - Review article

VL - 68

SP - 1174

EP - 1188

JO - Hepatology

JF - Hepatology

SN - 0270-9139

IS - 3

ER -